@article {Dauvillierse1754作者= {Yves Dauvilliers Elisa伊万格丽斯塔和露西Barateau里吉斯·洛佩兹和索菲{\ ' e} ne Chenini和卡罗琳Delbos年代{\ e} verine Beziat Isabelle Jaussent},标题={测量原发性嗜睡症状的},体积={92}={15},页面= {e1754——e1762} = {2019}, doi = {10.1212 / WNL。出版商0000000000007264}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={客观验证特发性嗜睡严重程度量表(公路),自我报告测量抽动症状,后果,和响应性治首页疗。方法其一ihs(由睡眠专家开发和验证患者{\ textquoteright}反馈)是由218名参与者填写(2.3 \ %缺失的数据)。210名参与者中完全完成了ihs,有57个未经处理和43名患者治疗特发性嗜睡(IH) 16岁或以上,37嗜睡症患者治疗1型(NT1),和73名对照没有睡意。ihs心理特性,判别诊断有效性和分数的变化与治疗评估。ihs结果显示良好的内部一致性和内容效度。因子分析表明2-component解决方案具有良好的可靠性表示满意的克伦巴赫α值。ihs分数可再生的没有变化的测试{\ textendash}重新测试评估(13和14个未经治疗的患者治疗)。聚合效度分析表明,ihs得分与白天嗜睡,抑郁症状,并在婴幼儿血管瘤患者的生活质量。ihs分数比未经处理的低治疗患者(5 {\ textendash} 8单位不同,没有上限效应)。截止值区分治疗和治疗病人是26/50(78.9敏感性55.8 \ %,特异性\ %)。ihs无毒IH病人的分数高于NT1和控制。最好的截断值区分治疗婴幼儿血管瘤病人和对照组22岁(敏感性91.1 \ %,特异性94.5 \ %),并与NT1 29。Conclusions The IHSS is a reliable and valid clinical tool for the quantification of IH symptoms and consequences that might be useful for patient identification, follow-up, and management.AUC=area under the curve; BDI-II=Beck Depression Inventory II; BMI=body mass index; CI=confidence interval; EDS=excessive daytime sleepiness; EQ-5D=European Quality of Life{\textendash}5 Dimensions; EQ-VAS=European Quality of Life visual analog scale; ESS=Epworth Sleepiness Scale; ICC=intraclass correlation coefficient; ICSD=International Classification of Sleep Disorders; IH=idiopathic hypersomnia; IHSS=Idiopathic Hypersomnia Severity Scale; KMO=Kaiser-Meyer-Olkin; MSL=mean sleep latency; MSLT=multiple sleep latency test; NT1=narcolepsy type 1; NT2=narcolepsy type 2; PSG=polysomnography; ROC=receiver operating characteristic; SOREMP=sleep-onset REM period}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/92/15/e1754}, eprint = {//www.ez-admanager.com/content/92/15/e1754.full.pdf}, journal = {Neurology} }